The HIV-1 reverse transcriptase connection domain from treatment-experienced patients contributes to AZT resistance

被引：0
|
作者：
Nikolenko, G. N.
Frankenberry, K. A.
Palmer, S.
Maldarelli, F.
Mellors, J. W.
Coffin, J. M.
Pathak, V. K.
机构：
[1] NCI, HIV Drug Resistance Program, Frederick, MD 21701 USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
来源：
ANTIVIRAL THERAPY | 2006年 / 11卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [31] A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
    Meyer, PR
    Matsuura, SE
    Mian, AM
    So, AG
    Scott, WA
    MOLECULAR CELL, 1999, 4 (01) : 35 - 43
  • [32] MULTIPLE MUTATIONS IN HIV-1 REVERSE-TRANSCRIPTASE CONFER HIGH-LEVEL RESISTANCE TO ZIDOVUDINE (AZT)
    LARDER, BA
    KEMP, SD
    SCIENCE, 1989, 246 (4934) : 1155 - 1158
  • [33] Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients
    Kakuda, T. N.
    Wade, J. R.
    Snoeck, E.
    Vis, P.
    Scholler-Gyure, M.
    Peeters, M. P.
    Corbett, C.
    Nijs, S.
    Vingerhoets, J.
    Leopold, L.
    De Smedt, G.
    Woodfall, B. J.
    Hoetelmans, R. M. W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 695 - 703
  • [34] Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
    Orrell, Catherine
    Felizarta, Franco
    Nell, Andre
    Kakuda, Thomas N.
    Lavreys, Ludo
    Nijs, Steven
    Tambuyzer, Lotke
    Van Solingen-Ristea, Rodica
    Tomaka, Frank L.
    AIDS RESEARCH AND TREATMENT, 2015, 2015
  • [35] Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection
    Sluis-Cremer, Nicolas
    Wainberg, Mark A.
    Schinazi, Raymond F.
    FUTURE MICROBIOLOGY, 2015, 10 (11) : 1773 - 1782
  • [36] INTERACTIONS OF THE HIV-1 REVERSE-TRANSCRIPTASE AZT-RESISTANT MUTANT WITH SUBSTRATES AND AZT-TP
    POKHOLOK, DK
    GUDIMA, SO
    YESIPOV, DS
    DOBRYNIN, VN
    RECHINSKY, VO
    KOCHETKOV, SN
    FEBS LETTERS, 1993, 325 (03) : 237 - 241
  • [37] Synthesis of AZT 5′-triphosphate mimics and their inhibitory effects on HIV-1 reverse transcriptase
    Wang, GY
    Boyle, N
    Chen, F
    Rajappan, V
    Fagan, P
    Brooks, JL
    Hurd, T
    Leeds, JM
    Rajwanshi, VK
    Jin, Y
    Prhavc, M
    Bruice, TW
    Cook, PD
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (27) : 6902 - 6913
  • [38] Synergistic inhibition of HIV-1 reverse transcriptase and HIV-1 replication by combining trovirdine with AZT, ddl and ddC in vitro
    Zhang, H
    Vrang, L
    Rydergard, C
    Ahgren, C
    Oberg, B
    ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1996, 7 (05): : 221 - 229
  • [39] EtravirineA Review of its Use in the Management of Treatment-Experienced Patients with HIV-1 Infection
    Jamie D. Croxtall
    Drugs, 2012, 72 : 847 - 869
  • [40] Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
    Pialoux, Gilles
    Marcelin, Anne-Genevieve
    Despiegel, Nicolas
    Espinas, Caroline
    Cawston, Helene
    Finkielsztejn, Laurent
    Laurisse, Audrey
    Aubin, Celine
    PLOS ONE, 2015, 10 (12):
12345